Abstract
IgA nephropathy (IgAN) is a progressive autoimmune disease caused by an accumulation of immunoglobulin A in the kidneys. Complications can include the development of chronic kidney disease (CKD) and early end stage renal disease which may result in early death. The NefIgArd trial (NCT03643965) demonstrated favorable results for targeted release formulation (TRF)-budesonide compared to placebo for the treatment of primary IgAN. This study aims to assess the budget impact of introducing TRF-budesonide as a novel oral treatment for adult patients with primary IgAN in the United States.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
